The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.00
Bid: 47.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.255%)
Open: 48.00
High: 48.00
Low: 48.00
Prev. Close: 48.00
MIG3 Live PriceLast checked at -
Maven Income and Growth VCT 3 is an Investment Trust

To achieve long-term capital appreciation and generate income for Shareholders by investing in a diversified portfolio of securities in smaller, unquoted UK companies and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of a Prospectus

13 Oct 2023 16:56

RNS Number : 1307Q
Maven Income & Growth VCT PLC
13 October 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA.

 

Joint Announcement by Maven Income and Growth VCT PLC, Maven Income and Growth VCT 3 PLC, Maven Income and Growth VCT 4 PLC and Maven Income and Growth VCT 5 PLC

Offers for Subscription

13 October 2023

 

The Board of Directors of Maven Income and Growth VCT PLC, Maven Income and Growth VCT 3 PLC, Maven Income and Growth VCT 4 PLC and Maven Income and Growth VCT 5 PLC (together the "Companies" and each a "Company") are pleased to announce that they have published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription for new Ordinary Shares of 10p each in each of the Companies to raise, in aggregate, up to £30 million including over-allotment facilities of up to, in aggregate, £10 million (before issue costs) (the "Offers" and each an "Offer").

The Companies have also published a joint Circular (the "Circular") seeking the approval of their respective shareholders for various matters, including obtaining shareholder approval of allotment and disapplication authorities in connection with the Offers and each Company giving notice of a General Meeting to be held on 9 November 2023 (the "General Meeting").

The Offers will open on 13 October 2023 and the deadline for receipt of applications is 9.00 am on 5 April 2024 in relation to the tax year 2023/24 and 5.00 pm on 26 April 2024 in relation to the tax year 2024/25. The Offers will close on 1 May 2024 unless the relevant Offer is fully subscribed by an earlier date or previously extended by the relevant Board to no later than 11 October 2024

Each Offer is conditional on the passing of certain resolutions at the relevant General Meeting.

Pursuant to individual offer agreements dated 13 October 2023 relating to each Offer between, among others, each relevant Company and Maven Capital Partners LLP ("Maven"), Maven, as the administrator of each Offer, will receive an offer administration fee of 2.5% of the application amount in relation to each accepted application, with reductions to the fee applying in certain cases (for instance, early applications under the Offers). Maven, as the investment manager of each Company, is a related party of each Company under the Listing Rules, and the payment of such a fee by the Company to Maven is a transaction to which Listing Rule 11.1.10R applies.

To obtain a copy of the Securities Note, private investors and financial advisers should call Maven Capital Partners LLP on 0141 306 7400. A downloadable version of the Securities Note will also be available from the Maven website: mavencp.com/vctoffer.

Copies of the Prospectus and Circular are available, free of charge, from Maven Capital Partners UK LLP at Kintyre House, 205 West George Street, Glasgow G2 2LW.

Copies of the Prospectus have been submitted to the National Storage Mechanism and will shortly be available for viewing online at the following website address: data.fca.org.uk/#/nsm/nationalstoragemechanism.

Any enquiries in respect of the Offers should be directed to:

Maven Capital Partners UK LLPTelephone: 0141 306 7400

E-mail: enquiries@mavencp.com

The information contained within this announcement is deemed by the Companies to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

 

Notes

 

This announcement does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase, any investment in any jurisdiction, nor shall it (or the fact of its distribution) form the basis of, or be relied on in connection with, any contract therefor.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PDIKZMMGKFZGFZM
Date   Source Headline
26th Apr 20242:40 pmRNSNet Asset Value - Dividend Investment Scheme
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:37 pmRNSIssue of Equity
28th Mar 202410:16 amRNSStatement re Offer for Subscription
27th Mar 202410:36 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:46 pmRNSUnaudited Net Asset Value
15th Mar 20245:18 pmRNSAnnual Financial Report
21st Feb 20244:24 pmRNSTransaction in Own Shares
8th Feb 202410:30 amRNSDirector/PDMR Shareholding
8th Feb 202410:28 amRNSDirector/PDMR Shareholding
8th Feb 202410:15 amRNSIssue of Equity
6th Feb 202411:07 amRNSDividend Declaration
19th Dec 20233:25 pmRNSIssue of Equity
18th Dec 20235:17 pmRNSUnaudited Net Asset Value
5th Dec 202311:42 amRNSDirectorate Change
9th Nov 20233:47 pmRNSResult of General Meeting
8th Nov 20234:01 pmRNSTransaction in Own Shares
7th Nov 20234:47 pmRNSTransaction in Own Shares
19th Oct 20234:15 pmRNSNet Asset Value
13th Oct 20234:56 pmRNSPublication of a Prospectus
25th Aug 20239:38 amRNSIssue of Equity
21st Aug 20233:28 pmRNSStatement re Dividend Investment Scheme
21st Jul 202312:52 pmRNSHalf-year Report
13th Jul 20234:04 pmRNSTransaction in Own Shares
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
30th Jun 20234:22 pmRNSNet Asset Value and Interim Dividend
2nd Jun 20239:41 amRNSIssue of Equity
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
26th Apr 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
24th Apr 202312:51 pmRNSResult of AGM
19th Apr 20234:49 pmRNSTransaction in Own Shares
19th Apr 20231:05 pmRNSNet Asset Value - Dividend Investment Scheme
5th Apr 202312:29 pmRNSIssue of Equity
4th Apr 202311:43 amRNSNet Asset Value(s)
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
14th Mar 20234:31 pmRNSAnnual Financial Report
3rd Mar 20239:53 amRNSIssue of Equity
21st Feb 20234:41 pmRNSTransaction in Own Shares
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202311:06 amRNSDirector/PDMR Shareholding - Replacement
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:08 amRNSDirector/PDMR Shareholding
8th Feb 20239:43 amRNSIssue of Equity
1st Feb 20233:23 pmRNSUnaudited NAV and Proposed Final Dividend
12th Dec 20223:41 pmRNSDirectorate Change
12th Dec 20223:34 pmRNSStatement re Director's Other Quoted Directorships
9th Nov 20223:00 pmRNSResult of General Meeting
4th Nov 20222:35 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.